Cargando…
Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic pulmonary disease with rising incidence. In this study the effectiveness of pirfenidone, as measured by longitudinal change in individual slope of forced vital capacity (FVC) prior to and after initiating pirfenidone t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700641/ https://www.ncbi.nlm.nih.gov/pubmed/33266405 http://dx.doi.org/10.3390/jcm9113763 |
_version_ | 1783616327892598784 |
---|---|
author | Krauss, Ekaterina Tello, Silke Wilhelm, Jochen Schmidt, Johanna Stoehr, Mark Seeger, Werner Dartsch, Ruth C. Crestani, Bruno Guenther, Andreas |
author_facet | Krauss, Ekaterina Tello, Silke Wilhelm, Jochen Schmidt, Johanna Stoehr, Mark Seeger, Werner Dartsch, Ruth C. Crestani, Bruno Guenther, Andreas |
author_sort | Krauss, Ekaterina |
collection | PubMed |
description | Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic pulmonary disease with rising incidence. In this study the effectiveness of pirfenidone, as measured by longitudinal change in individual slope of forced vital capacity (FVC) prior to and after initiating pirfenidone treatment, was evaluated in IPF patients recruited into the European registry for idiopathic pulmonary fibrosis (eurIPFreg). Secondary variables were the evaluation of the change in individual slope of diffusion capacity of the lungs for carbon monoxide (DLco), the Borg dyspnea scale, and six-minute walking distance (6MWD), as well as survival analyses. Results: Data of 122 eurIPFreg patients, who had at least two pulmonary function tests (PFTs) prior to or under treatment with pirfenidone, were analyzed by calculating slope-changes. The global analysis revealed an average slope change of +1.48 ± 0.28 (% per annum (p.a)) after start of treatment (p < 0.001), reflecting a reduction in annual FVC decline of approx. 50% under pirfenidone; it also showed a reduction in DLco, and increase in 6MWD (both p < 0.0001), as well as a flattening of the Borg dyspnea scale (p = 0.02). The median survival under treatment was 4.82 years. Patients with a more restrictive disease (FVC < 80% pred.), with a rapid progression (FVC decline >10% pred. p.a.), previous smokers and patients > 60 years of age seemed to profit more from pirfenidone treatment. Conclusions: We report the effectiveness of pirfenidone in a European “real world” IPF cohort with outcome data extending up to 9 years. Global analyses demonstrated a positive effect of pirfenidone on the decline of the lung function over time. Survival was dependent on Gender–Age–Physiology (GAP) score and age prior to therapy. |
format | Online Article Text |
id | pubmed-7700641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77006412020-11-30 Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) Krauss, Ekaterina Tello, Silke Wilhelm, Jochen Schmidt, Johanna Stoehr, Mark Seeger, Werner Dartsch, Ruth C. Crestani, Bruno Guenther, Andreas J Clin Med Article Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic pulmonary disease with rising incidence. In this study the effectiveness of pirfenidone, as measured by longitudinal change in individual slope of forced vital capacity (FVC) prior to and after initiating pirfenidone treatment, was evaluated in IPF patients recruited into the European registry for idiopathic pulmonary fibrosis (eurIPFreg). Secondary variables were the evaluation of the change in individual slope of diffusion capacity of the lungs for carbon monoxide (DLco), the Borg dyspnea scale, and six-minute walking distance (6MWD), as well as survival analyses. Results: Data of 122 eurIPFreg patients, who had at least two pulmonary function tests (PFTs) prior to or under treatment with pirfenidone, were analyzed by calculating slope-changes. The global analysis revealed an average slope change of +1.48 ± 0.28 (% per annum (p.a)) after start of treatment (p < 0.001), reflecting a reduction in annual FVC decline of approx. 50% under pirfenidone; it also showed a reduction in DLco, and increase in 6MWD (both p < 0.0001), as well as a flattening of the Borg dyspnea scale (p = 0.02). The median survival under treatment was 4.82 years. Patients with a more restrictive disease (FVC < 80% pred.), with a rapid progression (FVC decline >10% pred. p.a.), previous smokers and patients > 60 years of age seemed to profit more from pirfenidone treatment. Conclusions: We report the effectiveness of pirfenidone in a European “real world” IPF cohort with outcome data extending up to 9 years. Global analyses demonstrated a positive effect of pirfenidone on the decline of the lung function over time. Survival was dependent on Gender–Age–Physiology (GAP) score and age prior to therapy. MDPI 2020-11-22 /pmc/articles/PMC7700641/ /pubmed/33266405 http://dx.doi.org/10.3390/jcm9113763 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Krauss, Ekaterina Tello, Silke Wilhelm, Jochen Schmidt, Johanna Stoehr, Mark Seeger, Werner Dartsch, Ruth C. Crestani, Bruno Guenther, Andreas Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) |
title | Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) |
title_full | Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) |
title_fullStr | Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) |
title_full_unstemmed | Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) |
title_short | Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg) |
title_sort | assessing the effectiveness of pirfenidone in idiopathic pulmonary fibrosis: long-term, real-world data from european ipf registry (euripfreg) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700641/ https://www.ncbi.nlm.nih.gov/pubmed/33266405 http://dx.doi.org/10.3390/jcm9113763 |
work_keys_str_mv | AT kraussekaterina assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT tellosilke assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT wilhelmjochen assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT schmidtjohanna assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT stoehrmark assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT seegerwerner assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT dartschruthc assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT crestanibruno assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg AT guentherandreas assessingtheeffectivenessofpirfenidoneinidiopathicpulmonaryfibrosislongtermrealworlddatafromeuropeanipfregistryeuripfreg |